Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
for tags : Phase 1 save search
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb’s OPDIVO® (nivolumab)
Published: 2023-03-23 (Crawled : 13:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.52%
H: 0.46%
C: -0.9%
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 0.62%
H: 5.65%
C: 5.11%
bbp-398 opdivo lung pharma cancer trial phase 1
Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373
Published: 2023-03-23 (Crawled : 12:20) - biospace.com/
ENVB | $0.8989 -4.17% -4.35% 130K
|
Health Technology
|
| O: 2.56%
H: 0.04%
C: -5.0%
eb-373 study phase 1
FSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive Disorder
Published: 2023-03-22 (Crawled : 13:00) - biospace.com/
HUGE | $0.6167 1.22% 29K
|
Process Industries
|
| O: 0.65%
H: 3.21%
C: 0.0%
pharma candidate approval treatment trial potential phase 1 major depressive disorder
Plus Therapeutics Initiates Cohort 3 in Phase 1/Part A of the ReSPECT-LM Trial for Leptomeningeal MetastasesFirst data readout of Phase 1/Part A trial expected second half of 2023
Published: 2023-03-22 (Crawled : 12:00) - biospace.com/
PSTV | $1.67 -1.27% -1.28% 25K
|
Health Technology
|
| O: 3.12%
H: 1.39%
C: 0.0%
expected readout trial therapeutics plus phase 1
Plus Therapeutics Initiates Cohort 3 in Phase 1/Part A of the ReSPECT-LM Trial for Leptomeningeal Metastases
Published: 2023-03-22 (Crawled : 11:00) - globenewswire.com
PSTV | $1.67 -1.27% -1.28% 25K
|
Health Technology
|
| O: 3.12%
H: 1.39%
C: 0.0%
trial therapeutics plus phase 1
Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of FPI-2059, a Targeted Alpha Therapy (TAT) for the Treatment of Solid Tumors Expressing NTSR1
Published: 2023-03-20 (Crawled : 23:00) - biospace.com/
FUSN | $21.26 0.05% 0.05% 440K
|
Health Technology
|
| O: -2.17%
H: 3.69%
C: -1.48%
fpi-2059 tumors treatment pharmaceuticals therapy study phase 1
Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors
Published: 2023-03-16 (Crawled : 12:20) - biospace.com/
PYXS | $4.155 -8.28% -9.03% 670K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 7.46%
C: 7.46%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.55%
H: 1.07%
C: 0.77%
pyx-201 tumors trial phase 1
Primmune Therapeutics to Present New Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2023 American Association for Cancer Research (AACR) Annual Meeting
Published: 2023-03-14 (Crawled : 00:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
| Email alert
Add to watchlist
prtx007 research meeting association therapeutics cancer study phase 1
Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder
Published: 2023-03-08 (Crawled : 19:00) - biospace.com/
VTGN | $4.77 1.49% 1.47% 150K
|
Health Technology
|
| O: 2.12%
H: 2.52%
C: -5.6%
ph10 spray trial phase 1 major depressive disorder
Sernova Announces Initial Islet Transplantation in First Two Patients Enrolled in Second Cohort of its U.S. Phase 1/2 Clinical Trial for Treatment of Type 1 Diabetes
Published: 2023-03-08 (Crawled : 13:00) - biospace.com/
SEOVF | $0.3295 15.67% 29K
|
Health Technology
|
| O: 1.27%
H: 4.0%
C: -2.5%
treatment trial diabetes phase 1
Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
Published: 2023-03-07 (Crawled : 14:00) - biospace.com/
DYAI A | $1.61 1.26% 1.24% 14K
|
Health Technology
|
| O: -0.71%
H: 21.43%
C: 20.71%
dyai-100 covid-19 candidate protein vaccine trial update phase 1
Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201
Published: 2023-03-07 (Crawled : 14:00) - biospace.com/
CELZ | $4.82 0.21% 0.21% 22K
|
|
| O: 1.56%
H: 0.0%
C: -6.18%
SYNH | $42.98 0.0% 7.4M
|
Health Services
|
| O: 0.03%
H: 0.45%
C: -1.01%
celz-201 medical technology trial diabetes international phase 1
Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
Published: 2023-02-28 (Crawled : 14:00) - biospace.com/
ARWR | $22.33 -1.24% -1.25% 960K
|
Health Technology
|
| O: -0.46%
H: 2.06%
C: -0.46%
treatment ongoing study phase 1
Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1 Clinical Trial Evaluating OCU200 for the Treatment of Diabetic Macular Edema
Published: 2023-02-27 (Crawled : 23:00) - globenewswire.com
OCGN | News A | $1.315 -0.38% -0.38% 6.5M
|
Health Technology
|
| O: -0.06%
H: 5.6%
C: 2.13%
ocu200 treatment fda drug macular application trial submission diabetic phase 1
Codexis and Nestlé Health Science Announce Interim Results from Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency
Published: 2023-02-23 (Crawled : 22:00) - globenewswire.com
CDXS | $2.815 0.54% 0.53% 470K
|
Process Industries
|
| O: -1.82%
H: 0.0%
C: -12.24%
cdx-7108 health trial pancreatic exocrine pancreatic insufficiency phase 1
Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea, DARE-PDM1
Published: 2023-02-22 (Crawled : 15:00) - biospace.com/
DARE | $0.2838 -3.83% -3.98% 550K
|
Health Technology
|
| O: 0.93%
H: 4.59%
C: -1.83%
treatment potential bioscience study phase 1
Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV
Published: 2023-02-22 (Crawled : 13:00) - biospace.com/
IMCR | $55.71 1.77% 1.74% 450K
|
Manufacturing
|
| O: -1.52%
H: 2.86%
C: -0.17%
hiv therapy living phase 1
Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers Symposium
Published: 2023-02-16 (Crawled : 14:00) - globenewswire.com
BLCM | $0.0748 381.28% 6.1K
|
Health Technology
|
| O: 4.49%
H: 0.0%
C: -16.41%
bpx-601 symposium asco cancer prostate cancer phase 1
BioNova Announces First Patient Dosed in a Phase 1/2 Study of BN301 for the Treatment of Hematologic Malignancies in China
Published: 2023-02-13 (Crawled : 17:00) - sutrobio.com
STRO | $3.635 -3.58% -3.71% 520K
|
Health Technology
|
| O: -0.31%
H: 8.62%
C: -1.88%
bn301 treatment china study phase 1
Ocular Therapeutix™ Announces Interim 10-month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD
Published: 2023-02-11 (Crawled : 16:20) - globenewswire.com
OCUL | $5.22 -10.92% -12.26% 9.1M
|
Health Technology
| Email alert
Add to watchlist
treatment ongoing ocular trial phase 1
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.